Top 10 Questions Related to Factor VIIIΑ Mimetic Therapy for People with Hemophilia A
Emicizumab: the hemophilia A game-changer.
Alcedo Andrade PE, Mannucci PM, Kessler CM. Haematologica. 2024;109(5):1334-1347.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, et al. Blood. 2021;137(16):2231-2242.
Implementing shared decision-making in haemophilia care: best practice recommendations from a western European multi-stakeholder Delphi process.
Coffin D, Klamroth R, Crato M, et al. Haemophilia. 2026;32(3):680-690.
FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors.
Hermans C, Benson G, Matino D, et al.. J Thromb Haemost. 2026. [Epub ahead of print]
Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors.
Mancuso ME, Chan AKC, Shanmukhaiah C, et al. N Engl J Med. 2026;394(17):1696-1709.
Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4.
Matsushita T, Banchev A, Bovet J, et al. Blood Adv. 2026;10(20):6946-6953.
Non-factor therapies in hemophilia: mechanisms, clinical evidence, patient management, and future perspectives.
Nakajima Y, Nogami K. Adv Ther. 2026;43(6):2408-2420.
NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.
Nogami K, You CW, Park YS, et al. Blood. 2026;147(19):2261-2271.
WFH guidelines for the management of hemophilia, 3rd edition.
Srivastava A, Santagostino E, Dougall A, et al. Haemophilia. 2020;26(suppl 6):1-158.
Nonfactor Therapies for Hemophilia.
Young G. HemaSphere. 2023;7(6):e911.
Clinical Practice Guidelines
National Bleeding Disorders Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) Documents
MASAC develops recommendations and advisories on the treatment and management of hemophilia and other bleeding disorders in the United States.
World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia. 3rd Edition.
Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158.
Patient Advocacy Organizations and Resources
Hemophilia Federation of America (HFA)
The HFA is a patient advocacy organization serving the rare bleeding disorders community. It is a community-based, patient-centered organization committed to championing the needs of families living with debilitating bleeding disorders. It advocates for safe and effective therapies and quality, affordable health coverage.
National Bleeding Disorders Foundation (NBDF)
The NBDF (formerly the National Hemophilia Foundation) is dedicated to finding cures for inheritable blood and bleeding disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
WFH
The WFH is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world.
Top 10 Questions Related to Factor VIIIΑ Mimetic Therapy for People with Hemophilia A
Quick Hitting Activity
| Faculty: | Maya Bloomberg, MSN, APRN |
| Release: | 10/30/2026 |
| Expiration: | 10/30/2027 |
